Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Taipei Exchange - Delayed Quote TWD

TSH Biopharm Corporation Limited (8432.TWO)

Compare
52.90
+0.60
+(1.15%)
At close: April 2 at 1:30:13 PM GMT+8
Loading Chart for 8432.TWO
  • Previous Close 52.30
  • Open 52.70
  • Bid 52.60 x --
  • Ask 53.00 x --
  • Day's Range 52.50 - 53.00
  • 52 Week Range 51.70 - 71.10
  • Volume 8,400
  • Avg. Volume 49,587
  • Market Cap (intraday) 2.031B
  • Beta (5Y Monthly) 0.21
  • PE Ratio (TTM) 17.99
  • EPS (TTM) 2.94
  • Earnings Date --
  • Forward Dividend & Yield 1.28 (2.42%)
  • Ex-Dividend Date Jun 17, 2024
  • 1y Target Est --

TSH Biopharm Corporation Limited develops and markets pharmaceutical products in Taiwan and Asia. It offers products for cardiovascular, central nervous, gastrointestinal, and others. The company was founded in 1999 and is headquartered in Taipei city, Taiwan. TSH Biopharm Corporation Limited is a subsidiary of TTY Biopharm Company Limited.

www.tshbiopharm.com

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 8432.TWO

View More

Performance Overview: 8432.TWO

Trailing total returns as of 4/2/2025, which may include dividends or other distributions. Benchmark is TSEC CAPITALIZATION WEIGHTED ST (^TWII) .

YTD Return

8432.TWO
13.70%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
7.54%

1-Year Return

8432.TWO
8.18%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
4.06%

3-Year Return

8432.TWO
34.02%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
20.84%

5-Year Return

8432.TWO
15.79%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
120.40%

Compare To: 8432.TWO

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 8432.TWO

View More

Valuation Measures

Annual
As of 4/2/2025
  • Market Cap

    2.03B

  • Enterprise Value

    1.17B

  • Trailing P/E

    17.98

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.82

  • Price/Book (mrq)

    1.46

  • Enterprise Value/Revenue

    1.05

  • Enterprise Value/EBITDA

    5.77

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    10.14%

  • Return on Assets (ttm)

    6.55%

  • Return on Equity (ttm)

    9.29%

  • Revenue (ttm)

    1.12B

  • Net Income Avi to Common (ttm)

    113.09M

  • Diluted EPS (ttm)

    2.94

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    897.36M

  • Total Debt/Equity (mrq)

    1.26%

  • Levered Free Cash Flow (ttm)

    138.94M

Research Analysis: 8432.TWO

View More

Company Insights: 8432.TWO

Research Reports: 8432.TWO

View More

People Also Watch